FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

J H M Schellens

Research Profile

Chemicals & Drugs

Disorders

Neoplasms

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
C M Nijenhuis; J H M Schellens; J B A G Haanen; Jos H Beijnen
Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?
A Kort; Hilde Rosing; J H M Schellens; Alfred H Schinkel; E E Voest; G A Cirkel; M J X Hillebrand; Jos H Beijnen
Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry.
Nienke A G Lankheet; H Rosing; J H M Schellens; N Steeghs; Jos H Beijnen; A D R Huitema
Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of J H M Schellens (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: C M Nijenhuis; J H M Schellens; J B A G Haanen; Jos H Beijnen
Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?
Cancer treatment reviews 2013;39(4):305-12.
2013: A Kort; Hilde Rosing; J H M Schellens; Alfred H Schinkel; E E Voest; G A Cirkel; M J X Hillebrand; Jos H Beijnen
Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2013;925():117-23.
2013: Nienke A G Lankheet; H Rosing; J H M Schellens; N Steeghs; Jos H Beijnen; A D R Huitema
Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring.
Therapeutic drug monitoring 2013;35(2):168-76.
2013: N A G Lankheet; Hilde Rosing; J H M Schellens; Jos H Beijnen; M J X Hillebrand; A D R Huitema
Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
Biomedical chromatography : BMC 2013;27(4):466-76.
2013: L A Devriese; G Edwards; A Jenner; S Marchetti; M Mergui-Roelvink; F Peng; Larisa Reyderman; Jos H Beijnen; William Copalu; J Wanders; J H M Schellens
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
Investigational new drugs 2013;31(2):381-9.
2013: S Harmsen; R F Maas-Bakker; Irma Meijerman; J H Beijnen; J H M Schellens
PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2013;48(4-5):644-9.
2013: T P C Dorlo; N G L Jager; Jos H Beijnen; J H M Schellens
[Concomitant use of proton pump inhibitors and systemic corticosteroids].
Nederlands tijdschrift voor geneeskunde 2013;157(19):A5540.
2012: L A Devriese; G Edwards; A Jenner; S Marchetti; M Mergui-Roelvink; Larisa Reyderman; E E Voest; J Wanders; Petronella O Witteveen; Jos H Beijnen; J H M Schellens
Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
Cancer chemotherapy and pharmacology 2012;70(6):823-32.
2012: N G L Jager; Sabine C Linn; H Rosing; J H M Schellens; Jos H Beijnen
Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.
Breast cancer research and treatment 2012;133(2):793-8.
2012: D S Boss; William Copalu; Jos H Beijnen; H Glen; M Keesen; A Mazur; R Morrison; J P O'Brien; J H M Schellens; B Tait; J Wanders; T R J Evans
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.
British journal of cancer 2012;106(10):1598-604.
2012: A C Dubbelman; A Gebretensae; S H Gorman; L Nan; P Robertson; Hilde Rosing; J H M Schellens; M Tibben; Jos H Beijnen
Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;893-894():92-100.
2012: A C Dubbelman; A Gebretensae; L Lucas; Hilde Rosing; J H M Schellens; R Shumaker; Bas Thijssen; H Chen; Jos H Beijnen
Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;887-888():25-34.
2012: S L W Koolen; J H M Schellens; A H Schinkel; O van Tellingen; R A B van Waterschoot; J H Beijnen; A D R Huitema
From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.
Journal of clinical pharmacology 2012;52(3):370-80.
2012: Maarten J Deenen; C M P W Mandigers; Jos H Beijnen; Annemieke Cats; Marcel Soesan; Wim E Terpstra; J H M Schellens
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Nederlands tijdschrift voor geneeskunde 2012;156(48):A4934.
2012: W A van Leeuwen; H E Becker; L de Haan; J H M Schellens; R van Westrhenen
[The subclinical course of a paracetamol intoxication: pitfall for patient and clinician].
Tijdschrift voor psychiatrie 2012;54(6):555-9.
2012: Martijn L Manson; J H M Schellens; Pierre W Wijermans; Ellen J B Derissen; Jos H Beijnen
[Demethylating medication in myelodysplastic syndrome].
Nederlands tijdschrift voor geneeskunde 2012;156(4):A3167.
2012: Alberta Bergamo; C Gaiddon; J H Beijnen; J H M Schellens; Gianni Sava
Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
Journal of inorganic biochemistry 2012;106(1):90-9.
2011: J J Moes; Jos H Beijnen; A D R Huitema; S L W Koolen; J H M Schellens; B Nuijen
Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).
International journal of pharmaceutics 2011;420(2):244-50.
2011: Markus Joerger; P Baas; J H Beijnen; J A Burgers; A Burylo; D deJong; A D R Huitema; J H M Schellens
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Lung cancer (Amsterdam, Netherlands) 2011;74(2):310-7.
2011: M H G Langenberg; B Loembé; Martijn Lolkema; M Mergui-Roelvink; A Nol-Boekel; J Roodhart; J H M Schellens; Hendrik Verheul; E Brendel; O Christensen; J Krätzschmar; Petronella O Witteveen; Emile E Voest
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(11):2508-15.
2011: J.G. Coen van Hasselt; J H M Schellens; J H Beijnen; A H Boekhout; A D R Huitema
Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.
Clinical pharmacology and therapeutics 2011;90(1):126-32.
2011: T J Molloy; J H M Schellens; Emile E Voest; Astrid J Bosma; L A Devriese; Michael Hauptmann; H H Helgason; Laura J van't Veer
A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer.
British journal of cancer 2011;104(12):1913-9.
2011: S F Teunissen; N G L Jager; Hilde Rosing; Alfred H Schinkel; J H M Schellens; Jos H Beijnen
Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(19):1677-85.
2011: Bas Teunissen; Hilde Rosing; M Dominguez Seoane; L Brunsveld; J H M Schellens; Alfred H Schinkel; Jos H Beijnen
Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.
Journal of pharmaceutical and biomedical analysis 2011;55(3):518-26.
2011: Ron J Keizer; Y Funahashi; T Semba; J Wanders; J H Beijnen; J H M Schellens; A D R Huitema
Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.
The AAPS journal 2011;13(2):230-9.
2011: A C Dubbelman; Hilde Rosing; Bas Thijssen; L Lucas; William Copalu; J Wanders; J H M Schellens; Jos H Beijnen
Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(15-16):1149-55.
2011: Ron J Keizer; J H M Schellens; Jos H Beijnen; Alwin D R Huitema
Pharmacodynamic biomarkers in model-based drug development in oncology.
Current clinical pharmacology 2011;6(1):30-40.
2011: David Boss; Petronella O Witteveen; J van der Sar; Martijn Lolkema; Emile E Voest; P K Stockman; O Ataman; D Wilson; S Das; J H M Schellens
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(2):431-7.
2010: Bas Teunissen; Hilde Rosing; Alfred H Schinkel; J H M Schellens; Jos H Beijnen
Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review.
Analytica chimica acta 2010;683(1):21-37.
2010: Bas Teunissen; Hilde Rosing; Alfred H Schinkel; J H M Schellens; Jos H Beijnen
Review on the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and its phase I and phase II metabolites in biological matrices, foodstuff and beverages.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(31):3199-216.
2010: Bas Teunissen; Maria L H Vlaming; Hilde Rosing; J H M Schellens; Alfred H Schinkel; Jos H Beijnen
Development and validation of a liquid chromatography-tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces and eight selected tissues from mice.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(25):2353-62.
2010: Stefan Harmsen; Irma Meijerman; C L Febus; R F Maas-Bakker; Jos H Beijnen; J H M Schellens
PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line.
Cancer chemotherapy and pharmacology 2010;66(4):765-71.
2010: David Boss; Gary K Schwartz; M R Middleton; D D Amakye; H Swaisland; R S Midgley; M Ranson; S Danson; Hilary Calvert; R Plummer; C Morris; Richard Carvajal; L R Chirieac; J H M Schellens; G I Shapiro
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(4):884-94.
2010: Roos L Oostendorp; Petronella O Witteveen; B Schwartz; L D Vainchtein; Margaret Schot; A Nol; Hilde Rosing; Jos H Beijnen; Emile E Voest; J H M Schellens
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors.
Investigational new drugs 2010;28(2):163-70.
2010: Jan-Hendrik Beumer; N E Franke; R Tolboom; Tessa Buckle; Hilde Rosing; Luis Lopez-Lazaro; J H M Schellens; Jos H Beijnen; Olaf van Tellingen
Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.
Investigational new drugs 2010;28(2):145-55.
2010: M Joerger; A D R Huitema; S Krähenbühl; J H M Schellens; T Cerny; M Reni; E Zucca; F Cavalli; A J M Ferreri
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
British journal of cancer 2010;102(4):673-7.
2010: Andrew K L Goey; J H M Schellens; Jos H Beijnen; Alwin D R Huitema
[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Nederlands tijdschrift voor geneeskunde 2010;154():A1155.
2010: S L W Koolen; Jos H Beijnen; J H M Schellens
Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel.
Clinical pharmacology and therapeutics 2010;87(1):126-9.
2009: A G Lankheet; Michel J X Hillebrand; M H G Langenberg; Hilde Rosing; A D R Huitema; E E Voest; J H M Schellens; Jos H Beijnen
A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(29):3625-30.
2009: Bas Teunissen; Hilde Rosing; R H T Koornstra; Sabine C Linn; J H M Schellens; Alfred H Schinkel; Jos H Beijnen
Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(24):2519-29.
2009: S Harmsen; Irma Meijerman; Jos H Beijnen; J H M Schellens
Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor.
Cancer chemotherapy and pharmacology 2009;64(1):35-43.
2009: J H M Schellens; R Grouls; H J Guchelaar; D J Touw; G A Rongen; A de Boer; L M Van Bortel
The Dutch vision of clinical pharmacology.
Clinical pharmacology and therapeutics 2009;85(4):366-8.
2009: E E M Brouwers; M Söhne; S Kuipers; Eric C M van Gorp; J H M Schellens; Cornelis H W Koks; Jos H Beijnen; Alwin D R Huitema
Ciprofloxacin strongly inhibits clozapine metabolism: two case reports.
Clinical drug investigation 2009;29(1):59-63.
2008: Natalie M G M Appels; M J Bolijn; K Chan; T C Stephens; G Hoctin-Boes; M Middleton; Jos H Beijnen; J S de Bono; A L Harris; J H M Schellens
Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.
British journal of cancer 2008;98(12):1951-8.
2008: S Harmsen; Andries Koster; Jos H Beijnen; J H M Schellens; Irma Meijerman
Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(6):1166-71.
2008: Anthe S Zandvliet; Wandena S Siegel-Lakhai; Jos H Beijnen; William Copalu; M-C Etienne-Grimaldi; G Milano; J H M Schellens; Alwin D R Huitema
PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
Clinical pharmacology and therapeutics 2008;83(6):829-39.
2008: E E M Brouwers; Matthijs M Tibben; Dick Pluim; Hilde Rosing; H Boot; A Cats; J H M Schellens; Jos H Beijnen
Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin.
Analytical and bioanalytical chemistry 2008;391(2):577-85.
2008: Frank J P Hoebers; Dick Pluim; Augustinus A M Hart; Marcel Verheij; Alfons J M Balm; G Fons; Coen R N Rasch; J H M Schellens; L J A Stalpers; Harry Bartelink; Adrian C Begg
Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
Cancer chemotherapy and pharmacology 2008;61(6):1075-81.
2008: Wandena S Siegel-Lakhai; Anthe S Zandvliet; Alwin D R Huitema; Matthijs M Tibben; G Milano; V Girre; V Diéras; A King; E Richmond; Jantien Wanders; Jos H Beijnen; J H M Schellens
A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.
British journal of cancer 2008;98(8):1320-6.
2007: Markus Joerger; Alwin D R Huitema; manon huizing; P H B Willemse; A de Graeff; Hilde Rosing; J H M Schellens; Jos H Beijnen; Jan B Vermorken
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.
British journal of clinical pharmacology 2007;64(5):622-33.
2007: Stephan A Veltkamp; Hilde Rosing; Alwin D R Huitema; M R Fetell; A Nol; Jos H Beijnen; J H M Schellens
Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
Cancer chemotherapy and pharmacology 2007;60(5):635-42.
2007: Serena Marchetti; J H M Schellens
The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
British journal of cancer 2007;97(5):577-81.
2007: E E M Brouwers; Alwin D R Huitema; E N Bakker; J W Douma; K J M Schimmel; G van Weringh; P J de Wolf; J H M Schellens; Jos H Beijnen
Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry.
International archives of occupational and environmental health 2007;80(8):689-99.
2007: Jan-Hendrik Beumer; R C Garner; M B Cohen; S Galbraith; G F Duncan; T Griffin; Jos H Beijnen; J H M Schellens
Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.
Investigational new drugs 2007;25(4):327-34.
2007: S Harmsen; Irma Meijerman; Jos H Beijnen; J H M Schellens
The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.
Cancer treatment reviews 2007;33(4):369-80.
2007: Isa E L M Kuppens; Petronella O Witteveen; Margaret Schot; V M Schuessler; A Daehling; Jos H Beijnen; Emile E Voest; J H M Schellens
Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.
Investigational new drugs 2007;25(3):227-35.
2007: R J Keizer; Alwin D R Huitema; C W N Damen; J H M Schellens; J H Beijnen
[The pharmacokinetics of monoclonal antibodies].
Nederlands tijdschrift voor geneeskunde 2007;151(12):683-8.
2007: J H M Schellens; J H Beijnen
[Management recommendations in patients with methotrexate intoxication].
Nederlands tijdschrift voor geneeskunde 2007;151(6):337-41.
2007: E M Kemper; H J M van Kan; Peter Speelman; K de Gans; J H Beijnen; J H M Schellens
[Severe phenytoin intoxication in patients with hypoalbuminaemia].
Nederlands tijdschrift voor geneeskunde 2007;151(2):138-41.
2007: Stephan A Veltkamp; C Alderden-Los; A Sharma; Hilde Rosing; Jos H Beijnen; J H M Schellens
A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Cancer chemotherapy and pharmacology 2007;59(1):43-50.
2006: Stephan A Veltkamp; Michel J X Hillebrand; Hilde Rosing; Robert Jansen; E R Wickremsinhe; E J Perkins; J H M Schellens; Jos H Beijnen
Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
Journal of mass spectrometry : JMS 2006;41(12):1633-42.
2006: H H Helgason; C M F Kruijtzer; Alwin D R Huitema; S G Marcus; Wim W ten Bokkel Huinink; Margaret Schot; Jan H Schornagel; Jos H Beijnen; J H M Schellens
Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.
British journal of cancer 2006;95(7):794-800.
2006: Stephan A Veltkamp; Bas Thijssen; J S Garrigue; G Lambert; F Lallemand; F Binlich; Alwin D R Huitema; Bastiaan Nuijen; A Nol; Jos H Beijnen; J H M Schellens
A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.
British journal of cancer 2006;95(6):729-34.
2006: E E M Brouwers; Matthijs M Tibben; Hilde Rosing; Michel J X Hillebrand; Markus Joerger; J H M Schellens; Jos H Beijnen
Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Journal of mass spectrometry : JMS 2006;41(9):1186-94.
2006: Markus Joerger; Alwin D R Huitema; Willem Boogerd; JJ van der Sande; J H M Schellens; Jos H Beijnen
Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
Basic & clinical pharmacology & toxicology 2006;99(2):133-40.
2006: Markus Joerger; Tessa M Bosch; Valerie D Doodeman; Jos H Beijnen; Paul H M Smits; J H M Schellens
Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers.
European journal of clinical pharmacology 2006;62(8):681-4.
2006: J H van den Berg; Jos H Beijnen; Alfons J M Balm; J H M Schellens
Future opportunities in preventing cisplatin induced ototoxicity.
Cancer treatment reviews 2006;32(5):390-7.
2006: Markus Joerger; Alwin D R Huitema; H J G Desirée van den Bongard; P Baas; Jan H Schornagel; J H M Schellens; Jos H Beijnen
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
British journal of clinical pharmacology 2006;62(1):71-80.
2006: Maria L H Vlaming; K Mohrmann; Els Wagenaar; Dirk R de Waart; Ronald P J Oude Elferink; Jurjen S Lagas; Olaf van Tellingen; Liia D Vainchtein; Hilde Rosing; Jos H Beijnen; J H M Schellens; Alfred H Schinkel
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.
The Journal of pharmacology and experimental therapeutics 2006;318(1):319-27.
2006: I van den Broek; Rolf W Sparidans; Alwin D R Huitema; J H M Schellens; Jos H Beijnen
Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;837(1-2):49-58.
2006: M C W Gast; Johannes M G Bonfrer; E J van Dulken; L de Kock; E J Th Rutgers; J H M Schellens; J H Beijnen
SELDI-TOF MS serum protein profiles in breast cancer: assessment of robustness and validity.
Cancer biomarkers : section A of Disease markers 2006;2(6):235-48.
2006: Tessa M Bosch; Valerie D Doodeman; Paul H M Smits; Irma Meijerman; J H M Schellens; Jos H Beijnen
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Molecular diagnosis & therapy 2006;10(3):175-85.
2005: Wandena S Siegel-Lakhai; Mirjam Crul; Steven Zhang; Rolf W Sparidans; Dick Pluim; A Howes; B Solanki; Jos H Beijnen; J H M Schellens
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
British journal of cancer 2005;93(11):1222-9.
2005: Jan-Hendrik Beumer; Jeany M Rademaker-Lakhai; Hilde Rosing; Luis Lopez-Lazaro; Jos H Beijnen; J H M Schellens
Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
Investigational new drugs 2005;23(5):429-36.
2005: J F F Lekkerkerker; fred schobben; J T van Dissel; Y A Hekster; A W Hoes; G J Mulder; C Neef; M F Peeters; J M van Ree; C F H Rosmalen; H Schellekens; J H M Schellens; J Silberbusch
[Selective serotonin reuptake inhibitors (SSRI's) are not indicated for children and adolescents with depression].
Nederlands tijdschrift voor geneeskunde 2005;149(33):1870-1; author reply 1871-2.
2005: E E M Brouwers; Matthijs M Tibben; Markus Joerger; Olaf van Tellingen; Hilde Rosing; J H M Schellens; Jos H Beijnen
Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry.
Analytical and bioanalytical chemistry 2005;382(7):1484-90.
2005: Isa E L M Kuppens; Maria J van Maanen; Hilde Rosing; J H M Schellens; Jos H Beijnen
Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry.
Biomedical chromatography : BMC 2005;19(5):355-61.
2005: Jan-Hendrik Beumer; J H M Schellens; Jos H Beijnen
Hepatotoxicity and metabolism of trabectedin: a literature review.
Pharmacological research : the official journal of the Italian Pharmacological Society 2005;51(5):391-8.
2005: Markus Joerger; Alwin D R Huitema; Pieter L Meenhorst; J H M Schellens; Jos H Beijnen
Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Cancer chemotherapy and pharmacology 2005;55(5):488-96.
2005: Isa E L M Kuppens; Pauline Breedveld; Jos H Beijnen; J H M Schellens
Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.
Cancer investigation 2005;23(5):443-64.
2005: Isa E L M Kuppens; Tessa M Bosch; Maria J van Maanen; Hilde Rosing; A Fitzpatrick; Jos H Beijnen; J H M Schellens
Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
Cancer chemotherapy and pharmacology 2005;55(1):72-8.
2004: Nadja E Schoemaker; Isa E L M Kuppens; Vladimir M Moiseyenko; B Glimelius; M Kjaer; H Starkhammer; D J Richel; Rune Smaaland; K Bertelsen; J P Poulsen; E Voznyi; J Norum; D Fennelly; Kjell Magne Tveit; A Garin; G Gruia; A Mourier; D Sibaud; Patricia Lefebvre; Jos H Beijnen; J H M Schellens; Wim W ten Bokkel Huinink
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.
British journal of cancer 2004;91(8):1434-41.
2004: Loreley Calvet; Alexandre Santos; Alexander Valent; Marie-José Terrier-Lacombe; Paule Opolon; Jean-Louis Merlin; Geneviève Aubert; Jackie Morizet; J H M Schellens; Jean Bénard; Gilles Vassal
No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
British journal of cancer 2004;91(6):1205-12.
2004: Markus Joerger; J H M Schellens; J H Beijnen
Therapeutic drug monitoring of non-anticancer drugs in cancer patients.
Methods and findings in experimental and clinical pharmacology 2004;26(7):531-45.
2004: Joost Rothbarth; R A E M Tollenaar; J H M Schellens; J W R Nortier; Leo J Schultze Kool; Peter Kuppen; Gerard J Mulder; Cornelis J H van de Velde
Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives.
European journal of cancer (Oxford, England : 1990) 2004;40(12):1812-24.
2004: Ellen Stokvis; Hilde Rosing; Luis López-Lázaro; J H M Schellens; Jos H Beijnen
Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance.
Biomedical chromatography : BMC 2004;18(6):400-2.
2004: Thomas Kerbusch; Gerard Groenewegen; Ron A A Mathôt; Virginie M M Herben; Wim W ten Bokkel Huinink; M Swart; B Ambaum; Hilde Rosing; Sindy Jansen; Emile E Voest; Jos H Beijnen; J H M Schellens
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
British journal of cancer 2004;90(12):2268-77.
2004: Ellen Stokvis; Hilde Rosing; Mirjam Crul; M J Rieser; albert heck; J H M Schellens; Jos H Beijnen
Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(3):277-88.
2003: Charlotte van Kesteren; M M M de Vooght; Luis López-Lázaro; Ron A A Mathôt; J H M Schellens; José Jimeno; Jos H Beijnen
Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
Anti-cancer drugs 2003;14(7):487-502.
2003: Heleen A Bardelmeijer; Tessa Buckle; Mariët Ouwehand; Jos H Beijnen; J H M Schellens; Olaf van Tellingen
Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.
Laboratory animals 2003;37(3):181-7.
2003: H J G D van den Bongard; Dick Pluim; R C A M van Waardenburg; Miroslav Ravic; Jos H Beijnen; J H M Schellens
In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.
Anti-cancer drugs 2003;14(6):405-10.
2003: Philippe Chollet; Patrick Schöffski; K Weigang-Köhler; J H M Schellens; Hervé Cure; N Pavlidis; Viktor Grünwald; R De Boer; Jantien Wanders; Pierre Fumoleau
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
European journal of cancer (Oxford, England : 1990) 2003;39(9):1264-70.
2003: Charlotte van Kesteren; Ron A A Mathôt; Jos H Beijnen; J H M Schellens
Pharmacokinetic-pharmacodynamic guided trial design in oncology.
Investigational new drugs 2003;21(2):225-41.
2003: Ellen Stokvis; Lianda G A H Nan-Offeringa; Hilde Rosing; Luis López-Lázaro; J L Aceña; Elena Miranda; Aleksander V. Lyubimov; B S Levine; C D'Aleo; J H M Schellens; Jos H Beijnen
Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.
Journal of mass spectrometry : JMS 2003;38(5):548-54.
2003: Catherine Terret; S Zanetta; Henri Roché; J H M Schellens; Marije Faber; Jantien Wanders; Miroslav Ravic; Jean Pierre Droz
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).
European journal of cancer (Oxford, England : 1990) 2003;39(8):1097-104.
2003: J H M Schellens; A S T Planting; nico van zandwijk; J Ma; Marc Maliepaard; M E L van der Burg; MM de Boer-Dennert; E Brouwer; Ate van der Gaast; Martin J van den Bent; Jaap Verweij
Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.
British journal of cancer 2003;88(6):814-21.
2003: Jan Van den Brande; Patrick Schöffski; J H M Schellens; A D Roth; F Duffaud; K Weigang-Köhler; F Reinke; Jantien Wanders; R F de Boer; Jan B Vermorken; Pierre Fumoleau
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer.
British journal of cancer 2003;88(5):648-53.
2003: C M F Kruijtzer; Henk Boot; Jos H Beijnen; H L Lochs; F X Parnis; A S T Planting; J M G Pelgrims; R Williams; Ron A A Mathôt; Hilde Rosing; Margaret Schot; Harm van Tinteren; J H M Schellens
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(2):197-204.
2002: Mirjam Crul; Robert C A M van Waardenburg; Jos H Beijnen; J H M Schellens
DNA-based drug interactions of cisplatin.
Cancer treatment reviews 2002;28(6):291-303.
2002: C M F Kruijtzer; J H M Schellens; J Mezger; M E Scheulen; U Keilholz; Jos H Beijnen; Hilde Rosing; Ron A A Mathôt; S Marcus; Harm van Tinteren; Paul Baas
Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(23):4508-16.
2002: Charlotte van Kesteren; Ron A A Mathôt; Eric Raymond; Jean-Pierre Armand; Pierre Fumoleau; Cornelis J A Punt; Miroslav Ravic; Jantien Wanders; Jos H Beijnen; J H M Schellens
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
British journal of clinical pharmacology 2002;54(5):463-71.
2002: Charlotte van Kesteren; Ron A A Mathôt; Eric Raymond; Jean-Pierre Armand; Christian Dittrich; Herlinde Dumez; Henri Roché; Jean Pierre Droz; Cornelis J A Punt; Miroslav Ravic; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; J H M Schellens
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4065-73.
2002: Nadja E Schoemaker; Charlotte van Kesteren; Hilde Rosing; Sindy Jansen; M Swart; J Lieverst; Daniela Fraier; Massimo Breda; Cinzia Pellizzoni; Riccardo Spinelli; M Grazia Porro; Jos H Beijnen; J H M Schellens; Wim W ten Bokkel Huinink
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.
British journal of cancer 2002;87(6):608-14.
2002: Ellen Stokvis; Hilde Rosing; Luis López-Lázaro; I Rodriguez; José Jimeno; J G Supko; J H M Schellens; Jos H Beijnen
Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2002;37(9):992-1000.
2002: Eric Raymond; W W ten Bokkel Huinink; Julien Taïeb; Jos H Beijnen; Sandrine Faivre; Jantien Wanders; Miroslav Ravic; Pierre Fumoleau; Jean-Pierre Armand; J H M Schellens
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3508-21.
2002: Mirjam Crul; Hilde Rosing; GJ de Klerk; Ria Dubbelman; M Traiser; S Reichert; N G Knebel; J H M Schellens; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(12):1615-21.
2002: H J G Desirée van den Bongard; Ron A A Mathôt; Olaf van Tellingen; J H M Schellens; Jos H Beijnen
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Cancer chemotherapy and pharmacology 2002;50(1):16-24.
2002: Matthijs M Tibben; Jeany M Rademaker-Lakhai; John R Rice; Donald R Stewart; J H M Schellens; Jos H Beijnen
Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry.
Analytical and bioanalytical chemistry 2002;373(4-5):233-6.
2002: C M F Kruijtzer; Jos H Beijnen; Hilde Rosing; Wim W ten Bokkel Huinink; Margaret Schot; Roxanne C Jewell; Elaine M Paul; J H M Schellens
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(13):2943-50.
2002: Mirjam Crul; GJ de Klerk; M Swart; Laura J van't Veer; Daphne de Jong; Lucie Boerrigter; Peter A Palmer; CJ Bol; H Tan; G C de Gast; Jos H Beijnen; J H M Schellens
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(11):2726-35.
2002: H Bartelink; J H M Schellens; M Verheij
[The concomitant use of radiotherapy and chemotherapy for the treatment of solid malignant tumors].
Nederlands tijdschrift voor geneeskunde 2002;146(11):504-8.
2002: J H M Schellens; B Heinrich; M Lehnert; M E Gore; S B Kaye; Per Dombernowsky; Robert Paridaens; A T van Oosterom; Jaap Verweij; Walter J Loos; Hilary Calvert; Nicholas Pavlidis; H Cortes-Funes; Jantien Wanders; MW Roelvink; Cristiana Sessa; K Selinger; Paul Wissel; Teresa Gamucci; Axel R Hanauske
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Investigational new drugs 2002;20(1):83-93.
2002: C M F Kruijtzer; Jos H Beijnen; J H M Schellens
Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.
The oncologist 2002;7(6):516-30.
2002: Mirjam Crul; GJ de Klerk; M Swart; L Weiner; Peter A Palmer; CJ Bol; Jos H Beijnen; J H M Schellens
Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors.
European journal of drug metabolism and pharmacokinetics 2002;27(1):61-5.
2002: Harry Bartelink; J H M Schellens; Marcel Verheij
The combined use of radiotherapy and chemotherapy in the treatment of solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(2):216-22.
2002: Francesco Caponigro; Christian Dittrich; J B Sorensen; J H M Schellens; Florence Duffaud; L Paz Ares; Denis Lacombe; Christine de Balincourt; Pierre Fumoleau
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(1):70-4.
2001: Charlotte van Kesteren; R A Mathĵt; Luis López-Lázaro; Esteban Cvitkovic; Abdelkrim Taamma; José Jimeno; Cecilia Guzman; J H M Schellens; Jean-Louis Misset; Etienne Brain; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
Cancer chemotherapy and pharmacology 2001;48(6):459-66.
2001: Mirte M Malingré; J H M Schellens; Olaf van Tellingen; Mariët Ouwehand; Heleen A Bardelmeijer; Hilde Rosing; FJ Koopman; Margaret Schot; Wim W ten Bokkel Huinink; Jos H Beijnen
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
British journal of cancer 2001;85(10):1472-7.
2001: Heleen A Bardelmeijer; Mariët Ouwehand; Jos H Beijnen; J H M Schellens; Olaf van Tellingen
Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2001;763(1-2):201-6.
2001: Nadja E Schoemaker; Enrico Frigerio; Daniela Fraier; J H M Schellens; Hilde Rosing; Sindy Jansen; Jos H Beijnen
High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;763(1-2):173-83.
2001: Thomas Kerbusch; R A Mathĵt; HJ Keizer; J Ouwerkerk; Sjoerd Rodenhuis; J H M Schellens; Jos H Beijnen
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
European journal of clinical pharmacology 2001;57(6-7):467-77.
2001: J H M Schellens; A S T Planting; J Ma; Marc Maliepaard; A de Vos; MM de Boer-Dennert; Jaap Verweij
Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer.
Anti-cancer drugs 2001;12(8):667-75.
2001: Rolf W Sparidans; Hilde Rosing; Michel J X Hillebrand; Luis López-Lázaro; José Jimeno; Ignasio Manzanares; Charlotte van Kesteren; Esteban Cvitkovic; A T van Oosterom; J H M Schellens; Jos H Beijnen
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.
Anti-cancer drugs 2001;12(8):653-66.
2001: E Marleen Kemper; B Jansen; Kenneth Brouwer; J H M Schellens; Jos H Beijnen; Olaf van Tellingen
Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(1):135-43.
2001: Mirte M Malingré; Wim W ten Bokkel Huinink; K Duchin; J H M Schellens; Jos H Beijnen
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
Anti-cancer drugs 2001;12(7):591-3.
2001: J H M Schellens; Per Dombernowsky; J Cassidy; R Epelbaum; L Dirix; E H Cox; Jantien Wanders; F Calabresi; Robert Paridaens; S Monfardini; J Wolff; Walter J Loos; Jaap Verweij; Nicholas Pavlidis; Axel R Hanauske
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9.
Anti-cancer drugs 2001;12(7):583-90.
2001: Rolf W Sparidans; Ellen Stokvis; José Jimeno; Luis López-Lázaro; J H M Schellens; Jos H Beijnen
Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.
Anti-cancer drugs 2001;12(7):575-82.
2001: Mirte M Malingré; Wim W ten Bokkel Huinink; M Mackay; J H M Schellens; Jos H Beijnen
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel.
European journal of clinical pharmacology 2001;57(4):305-7.
2001: Thomas Kerbusch; Ron A A Mathôt; HJ Keizer; GP Kaijser; J H M Schellens; Jos H Beijnen
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(7):967-75.
2001: H J G Desirée van den Bongard; R A Mathĵt; Willem Boogerd; Jan H Schornagel; Marcel Soesan; J H M Schellens; Jos H Beijnen
Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure.
Cancer chemotherapy and pharmacology 2001;47(6):537-40.
2001: Mirte M Malingré; Jos H Beijnen; J H M Schellens
Oral delivery of taxanes.
Investigational new drugs 2001;19(2):155-62.
2001: Bastiaan Nuijen; Marjan Bouma; J H M Schellens; Jos H Beijnen
Progress in the development of alternative pharmaceutical formulations of taxanes.
Investigational new drugs 2001;19(2):143-53.
2001: Marc Maliepaard; George L Scheffer; Ian F Faneyte; Margôt van Gastelen; Adriana C L M Pijnenborg; Alfred H Schinkel; Marc J van de Vijver; Rik J Scheper; J H M Schellens
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
Cancer research 2001;61(8):3458-64.
2001: Mirte M Malingré; Jos H Beijnen; Hilde Rosing; FJ Koopman; Olaf van Tellingen; K Duchin; Wim W ten Bokkel Huinink; M Swart; J Lieverst; J H M Schellens
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Cancer chemotherapy and pharmacology 2001;47(4):347-54.
2001: Mirte M Malingré; Jos H Beijnen; Hilde Rosing; FJ Koopman; Olaf van Tellingen; K Duchin; Wim W ten Bokkel Huinink; M Swart; J Lieverst; J H M Schellens
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
Anti-cancer drugs 2001;12(4):351-8.
2001: Jetske M Meerum Terwogt; Wim W ten Bokkel Huinink; J H M Schellens; Margaret Schot; IA Mandjes; M G Zurlo; M Rocchetti; Hilde Rosing; FJ Koopman; Jos H Beijnen
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.
Anti-cancer drugs 2001;12(4):315-23.
2001: Marc Maliepaard; Margôt van Gastelen; A Tohgo; FREDERICK HAUSHEER; Robert C A M van Waardenburg; Laurina A de Jong; Dick Pluim; Jos H Beijnen; J H M Schellens
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):935-41.
2001: Mirjam Crul; GJ de Klerk; Jos H Beijnen; J H M Schellens
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
Anti-cancer drugs 2001;12(3):163-84.
2001: M Crul; H J G Desirée van den Bongard; Matthijs M Tibben; Olaf van Tellingen; G Sava; J H M Schellens; Jos H Beijnen
Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry.
Fresenius' journal of analytical chemistry 2001;369(5):442-5.
2001: Mirte M Malingré; Dick J Richel; Jos H Beijnen; Hilde Rosing; FJ Koopman; Wim W ten Bokkel Huinink; Margaret Schot; J H M Schellens
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1160-6.
2001: Mirte M Malingré; Jos H Beijnen; Hilde Rosing; FJ Koopman; Roxanne C Jewell; Elaine M Paul; Wim W ten Bokkel Huinink; J H M Schellens
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
British journal of cancer 2001;84(1):42-7.
2001: Thomas Kerbusch; J de Kraker; HJ Keizer; J W van Putten; Harry J M Groen; Rob L Jansen; J H M Schellens; Jos H Beijnen
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
Clinical pharmacokinetics 2001;40(1):41-62.
2001: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.
British journal of clinical pharmacology 2001;51(1):61-70.
2000: Charlotte van Kesteren; Esteban Cvitkovic; Abdelkrim Taamma; Luis López-Lázaro; José Jimeno; Cecilia Guzman; R A Math t; J H M Schellens; Jean-Louis Misset; Etienne Brain; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4725-32.
2000: J H M Schellens; Mirte M Malingré; C M F Kruijtzer; Heleen A Bardelmeijer; Olaf van Tellingen; A H Schinkel; Jos H Beijnen
Modulation of oral bioavailability of anticancer drugs: from mouse to man.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2000;12(2):103-10.
2000: Mirte M Malingré; J H M Schellens; Olaf van Tellingen; Hilde Rosing; FJ Koopman; K Duchin; Wim W Ten Bokkel Huinink; M Swart; Jos H Beijnen
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.
Anti-cancer drugs 2000;11(10):813-20.
2000: Bastiaan Nuijen; Marjan Bouma; Consuelo Manada; José Jimeno; J H M Schellens; Auke Bult; Jos H Beijnen
Pharmaceutical development of anticancer agents derived from marine sources.
Anti-cancer drugs 2000;11(10):793-811.
2000: H J G Desirée van den Bongard; Ron A A Mathôt; Jos H Beijnen; J H M Schellens
Pharmacokinetically guided administration of chemotherapeutic agents.
Clinical pharmacokinetics 2000;39(5):345-67.
2000: Heleen A Bardelmeijer; Jos H Beijnen; Kenneth Brouwer; Hilde Rosing; Willem Nooijen; J H M Schellens; Olaf van Tellingen
Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4416-21.
2000: johan jonker; Johan W Smit; Remco F Brinkhuis; Marc Maliepaard; Jos H Beijnen; J H M Schellens; Alfred H Schinkel
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Journal of the National Cancer Institute 2000;92(20):1651-6.
2000: Jetske M Meerum Terwogt; Olaf van Tellingen; VR Nannan Panday; manon huizing; J H M Schellens; Wim W ten Bokkel Huinink; M U Boschma; Giuseppe Giaccone; Cindy Veenhof; Jos H Beijnen
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
Anti-cancer drugs 2000;11(9):687-94.
2000: Alwin D R Huitema; K D Smits; Ron A A Mathôt; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
The clinical pharmacology of alkylating agents in high-dose chemotherapy.
Anti-cancer drugs 2000;11(7):515-33.
2000: Heleen A Bardelmeijer; Olaf van Tellingen; J H M Schellens; Jos H Beijnen
The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
Investigational new drugs 2000;18(3):231-41.
2000: Teresa Gamucci; Robert Paridaens; B Heinrich; J H M Schellens; Nicholas Pavlidis; Jaap Verweij; Cristiana Sessa; S Kaye; MW Roelvink; Jantien Wanders; Axel R Hanauske
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(7):793-7.
2000: Rob A J Kuiper; Mirte M Malingré; Jos H Beijnen; J H M Schellens
Cyclosporine-induced anaphylaxis.
The Annals of pharmacotherapy 2000;34(7-8):858-61.
2000: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Clinical pharmacology and therapeutics 2000;67(6):621-30.
2000: Mirte M Malingré; JM Terwogt; Jos H Beijnen; Hilde Rosing; FJ Koopman; Olaf van Tellingen; K Duchin; Wim W Ten Bokkel Huinink; M Swart; J Lieverst; J H M Schellens
Phase I and pharmacokinetic study of oral paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2468-75.
2000: Thomas Kerbusch; Alwin D R Huitema; J Ouwerkerk; HJ Keizer; Ron A A Mathôt; J H M Schellens; Jos H Beijnen
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
British journal of clinical pharmacology 2000;49(6):555-61.
2000: George L Scheffer; Marc Maliepaard; Adriana C L M Pijnenborg; Margôt van Gastelen; Mariska C de Jong; Anouk B Schroeijers; Dorina M van der Kolk; J D Allen; Douglas Ross; Paul Van Der Valk; W S Dalton; J H M Schellens; Rik J Scheper
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
Cancer research 2000;60(10):2589-93.
2000: Jaap Verweij; J H M Schellens; Jos H Beijnen; L Pronk; M Bo; V Lustig; H van Tinteren; M Mackay; Wim W ten Bokkel Huinink
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Anti-cancer drugs 2000;11(4):249-55.
2000: Jetske M Meerum Terwogt; Matthijs M Tibben; H Welbank; J H M Schellens; Jos H Beijnen
Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry.
Fresenius' journal of analytical chemistry 2000;366(3):298-302.
2000: J H M Schellens; Marc Maliepaard; Rik J Scheper; George L Scheffer; johan jonker; Johan W Smit; Jos H Beijnen; Alfred H Schinkel
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Annals of the New York Academy of Sciences 2000;922():188-94.
2000: C M F Kruijtzer; Jos H Beijnen; M Swart; J H M Schellens
Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature.
Cancer chemotherapy and pharmacology 2000;45(5):428-31.
2000: Hilde Rosing; V Lustig; LJ van Warmerdam; manon huizing; Wim W ten Bokkel Huinink; J H M Schellens; Sjoerd Rodenhuis; A Bult; Jos H Beijnen
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Cancer chemotherapy and pharmacology 2000;45(3):213-8.
1999: Jetske M Meerum Terwogt; Mirte M Malingré; Jos H Beijnen; Wim W ten Bokkel Huinink; Hilde Rosing; FJ Koopman; Olaf van Tellingen; M Swart; J H M Schellens
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3379-84.
1999: Dick Pluim; Marc Maliepaard; Robert C A M van Waardenburg; Jos H Beijnen; J H M Schellens
32P-postlabeling assay for the quantification of the major platinum-DNA adducts.
Analytical biochemistry 1999;275(1):30-8.
1999: VR Nannan Panday; LJ van Warmerdam; manon huizing; Wim W ten Bokkel Huinink; J H M Schellens; Jos H Beijnen
A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.
Journal of cancer research and clinical oncology 1999;125(11):615-20.
1999: A S T Planting; J H M Schellens; M E L van der Burg; MM de Boer-Dennert; B Winograd; Gerrit Stoter; Jaap Verweij
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
Anti-cancer drugs 1999;10(9):821-7.
1999: Miranda Verschraagen; C H Koks; J H M Schellens; Jos H Beijnen
P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.
Pharmacological research : the official journal of the Italian Pharmacological Society 1999;40(4):301-6.
1999: Marc Maliepaard; Margôt van Gastelen; Laurina A de Jong; Dick Pluim; Robert C A M van Waardenburg; M C Ruevekamp-Helmers; BG Floot; J H M Schellens
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Cancer research 1999;59(18):4559-63.
1999: Olaf van Tellingen; manon huizing; VR Panday; J H M Schellens; Willem Nooijen; Jos H Beijnen
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
British journal of cancer 1999;81(2):330-5.
1999: Virginie M M Herben; Hilde Rosing; Wim W ten Bokkel Huinink; Desiree M van Zomeren; Diane Batchelor; E Doyle; F D Beusenberg; Jos H Beijnen; J H M Schellens
Oral topotecan: bioavailablity and effect of food co-administration.
British journal of cancer 1999;80(9):1380-6.
1999: VR Panday; Wim W ten Bokkel Huinink; Jan B Vermorken; Hilde Rosing; FJ Koopman; M Swart; J H M Schellens; Jos H Beijnen
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Pharmacological research : the official journal of the Italian Pharmacological Society 1999;40(1):67-74.
1999: Virginie M M Herben; R van Gijn; J H M Schellens; Margaret Schot; J Lieverst; Michel J X Hillebrand; Nadja E Schoemaker; M G Porro; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1906-14.
1999: Virginie M M Herben; J H M Schellens; M Swart; G Gruia; L Vernillet; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1897-905.
1999: Hilde Rosing; Desiree M van Zomeren; E Doyle; W W ten Bokkel; J H M Schellens; Auke Bult; Jos H Beijnen
Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.
Journal of chromatography. B, Biomedical sciences and applications 1999;727(1-2):191-203.
1999: JM Terwogt; J H M Schellens; Wim W Ten Bokkel Huinink; Jos H Beijnen
Clinical pharmacology of anticancer agents in relation to formulations and administration routes.
Cancer treatment reviews 1999;25(2):83-101.
1999: Lia van Zuylen; J H M Schellens; Swan Hoo Goey; LC Pronk; MM de Boer-Dennert; Walter J Loos; J Ma; Gerrit Stoter; Jaap Verweij
Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combination with cisplatin and etoposide in patients with non-small cell lung cancer.
Anti-cancer drugs 1999;10(4):361-8.
1999: Virginie M M Herben; VR Panday; Dick J Richel; J H M Schellens; Nine van der Vange; Hilde Rosing; F D Beusenberg; Solange Hearn; E Doyle; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):747-55.
1999: M de Graaff; Marc Maliepaard; Dick Pluim; B J Floot; Ineke Slaper-Cortenbach; J H M Schellens
In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM.
Anti-cancer drugs 1999;10(2):213-8.
1999: VR Nannan Panday; Ronald de Wit; Jan H Schornagel; Margaret Schot; Hilde Rosing; J Lieverst; Wim W ten Bokkel Huinink; J H M Schellens; Jos H Beijnen
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Cancer chemotherapy and pharmacology 1999;44(4):349-53.
1999: VR Panday; LJ van Warmerdam; manon huizing; Sjoerd Rodenhuis; J H M Schellens; Jos H Beijnen
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.
Cancer chemotherapy and pharmacology 1999;43(5):435-8.
1999: C J H Gerrits; J H M Schellens; Howard A Burris; John R Eckardt; A S T Planting; M E L van der Burg; Gladys I Rodriguez; Walter J Loos; V van Beurden; IR Hudson; Daniel Von Hoff; Jaap Verweij
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(1):69-75.
1998: Kristel M L Crommentuyn; J H M Schellens; JD Van den Berg; Jos H Beijnen
In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.
Cancer treatment reviews 1998;24(5):345-66.
1998: VR Panday; Wim W ten Bokkel Huinink; Hilde Rosing; FJ Koopman; Michel J X Hillebrand; Ria Dubbelman; Olaf van Tellingen; J H M Schellens; Jos H Beijnen
Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
Anti-cancer drugs 1998;9(8):665-73.
1998: VR Panday; manon huizing; LJ van Warmerdam; Ria Dubbelman; IA Mandjes; J H M Schellens; Wim W Ten Bokkel Huinink; Jos H Beijnen
Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;38(3):231-6.
1998: Virginie M M Herben; Wim W ten Bokkel Huinink; J H M Schellens; Jos H Beijnen
Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
Pharmacy world & science : PWS 1998;20(4):161-72.
1998: C J H Gerrits; Howard A Burris; J H M Schellens; A S T Planting; M E van den Burg; Gladys I Rodriguez; V van Beurden; Walter J Loos; IR Hudson; S Fields; Jaap Verweij; Daniel Von Hoff
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 1998;34(7):1030-5.
1998: J Ma; M Maliepaard; Kees Nooter; Walter J Loos; HJ Kolker; Jaap Verweij; Gerrit Stoter; J H M Schellens
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
British journal of cancer 1998;77(10):1645-52.
1998: C J H Gerrits; Howard A Burris; J H M Schellens; John R Eckardt; A S T Planting; M E L van der Burg; Gladys I Rodriguez; Walter J Loos; V van Beurden; IR Hudson; S Fields; Daniel Von Hoff; Jaap Verweij
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1153-8.
1998: LC Pronk; Dirk Schrijvers; J H M Schellens; Ernst A de Bruijn; A S T Planting; D Locci-Tonelli; V Groult; Jaap Verweij; AT van Oosterom
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Seminars in oncology 1998;25(1 Suppl 2):23-8.
1998: VR Nannan Panday; LJ van Warmerdam; manon huizing; Wim W ten Bokkel Huinink; Jan B Vermorken; Giuseppe Giaccone; Cindy Veenhof; J H M Schellens; Jos H Beijnen
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
Clinical drug investigation 1998;15(4):327-35.
1998: Rob A J Kuiper; J H M Schellens; G H Blijham; Jos H Beijnen; E E Voest
Clinical research on antiangiogenic therapy.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;37(1):1-16.
1998: J Ma; M Maliepaard; Kees Nooter; Antonius W M Boersma; Jaap Verweij; Gerrit Stoter; J H M Schellens
Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
Cancer chemotherapy and pharmacology 1998;41(4):307-16.
1998: LC Pronk; Dirk Schrijvers; J H M Schellens; Ernst A de Bruijn; A S T Planting; D Locci-Tonelli; V Groult; Jaap Verweij; AT van Oosterom
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
British journal of cancer 1998;77(1):153-8.
1998: J Ma; M Maliepaard; HJ Kolker; Jaap Verweij; J H M Schellens
Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1.
Cancer chemotherapy and pharmacology 1998;41(3):186-92.
1997: Mirjam Crul; J H M Schellens; Jos H Beijnen; Marc Maliepaard
Cisplatin resistance and DNA repair.
Cancer treatment reviews 1997;23(5-6):341-66.
1997: Walter J Loos; Alex Sparreboom; Jaap Verweij; Kees Nooter; Gerrit Stoter; J H M Schellens
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;694(2):435-41.
1997: Geert-Jan Creemers; C J H Gerrits; John R Eckardt; J H M Schellens; Howard A Burris; A S T Planting; Gladys I Rodriguez; Walter J Loos; IR Hudson; C Broom; Jaap Verweij; Daniel Von Hoff
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1087-93.
1997: LC Pronk; J H M Schellens; A S T Planting; Martin J van den Bent; P H E Hilkens; M E L van der Burg; MM de Boer-Dennert; J Ma; C Blanc; M Harteveld; R Bruno; Gerrit Stoter; Jaap Verweij
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1071-9.
1997: J H M Schellens; W Van de Vrie; Walter J Loos; HJ Kolker; Jaap Verweij; Gerrit Stoter; N M Durante; A M Eggermont
Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wag/Rij rats.
Cancer chemotherapy and pharmacology 1997;41(1):48-52.
1997: C J H Gerrits; M J A de Jonge; J H M Schellens; Gerrit Stoter; Jaap Verweij
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
British journal of cancer 1997;76(7):952-62.
1997: C J H Gerrits; J H M Schellens; Geert-Jan Creemers; Paul Wissel; A S T Planting; J F Pritchard; S DePee; MM de Boer-Dennert; M Harteveld; Jaap Verweij
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
British journal of cancer 1997;76(7):946-51.
1997: A S T Planting; S Kho; M E L van der Burg; H Goey; J H M Schellens; Martin J van den Bent; Ate van der Gaast; MM de Boer-Dennert; Gerrit Stoter; Jaap Verweij
A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
Cancer chemotherapy and pharmacology 1997;40(4):347-52.
1996: A S T Planting; M E L van der Burg; Swan Hoo Goey; J H M Schellens; C Vecht; MM de Boer-Dennert; Gerrit Stoter; Jaap Verweij
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.
European journal of cancer (Oxford, England : 1990) 1996;32A(11):2026-8.
1996: Geert-Jan Creemers; C J H Gerrits; J H M Schellens; A S T Planting; M E L van der Burg; V van Beurden; MM de Boer-Dennert; M Harteveld; Walter J Loos; IR Hudson; Gerrit Stoter; Jaap Verweij
Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(9):2540-5.
1996: Ronald de Wit; Jos H Beijnen; Olaf van Tellingen; J H M Schellens; MM de Boer-Dennert; Jaap Verweij
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
British journal of cancer 1996;74(2):323-6.
1996: J H M Schellens; J Ma; A S T Planting; M E L van der Burg; E van Meerten; MM de Boer-Dennert; P I M Schmitz; Gerrit Stoter; Jaap Verweij
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
British journal of cancer 1996;73(12):1569-75.
1996: J H M Schellens; Geert-Jan Creemers; Jos H Beijnen; Hilde Rosing; MM de Boer-Dennert; M McDonald; B Davies; Jaap Verweij
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
British journal of cancer 1996;73(10):1268-71.
1996: Walter J Loos; Gerrit Stoter; Jaap Verweij; J H M Schellens
Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.
Journal of chromatography. B, Biomedical applications 1996;678(2):309-15.
1996: Martin J van den Bent; J H M Schellens; Peter A E Sillevis Smitt; Charles J Vecht
[Chemotherapy in brain tumors].
Nederlands tijdschrift voor geneeskunde 1996;140(13):702-6.
1996: C J H Gerrits; Geert-Jan Creemers; J H M Schellens; Paul Wissel; A S T Planting; R Kunka; K Selinger; MM de Boer-Dennert; Y Marijnen; M Harteveld; Jaap Verweij
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
British journal of cancer 1996;73(6):744-50.
1996: J H M Schellens; LC Pronk; Jaap Verweij
Emerging drug treatments for solid tumours.
Drugs 1996;51(1):45-72.
1996: W Van de Vrie; J H M Schellens; W J Loss; HJ Kolker; J Verwey; Gerrit Stoter; N M Durante; Alexander M M Eggermont
Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model.
Journal of cancer research and clinical oncology 1996;122(7):403-8.
1996: J Ma; Gerrit Stoter; Jaap Verweij; J H M Schellens
Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations.
Cancer chemotherapy and pharmacology 1996;38(4):391-4.
1996: LJ van Warmerdam; Geert-Jan Creemers; Sjoerd Rodenhuis; Hilde Rosing; MM de Boer-Dennert; J H M Schellens; Wim W ten Bokkel Huinink; brian e davies; R A Maes; Jaap Verweij; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
Cancer chemotherapy and pharmacology 1996;38(3):254-60.
1996: J Ma; Jaap Verweij; A S T Planting; HJ Kolker; Walter J Loos; MM de Boer-Dennert; M E L van der Burg; Gerrit Stoter; J H M Schellens
Docetaxel and paclitaxel inhibit DNA-adduct formation and intracellular accumulation of cisplatin in human leukocytes.
Cancer chemotherapy and pharmacology 1996;37(4):382-4.
1995: A S T Planting; M E L van der Burg; Swan Hoo Goey; J H M Schellens; Martin J van den Bent; MM de Boer-Dennert; G Stoter; J Verweij
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(6):613-5.
1995: J Ma; Jaap Verweij; A S T Planting; MM de Boer-Dennert; H E van Ingen; M E L van der Burg; G Stoter; J H M Schellens
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
British journal of cancer 1995;71(3):512-7.
1995: LJ van Warmerdam; Jaap Verweij; J H M Schellens; Hilde Rosing; brian e davies; MM de Boer-Dennert; R A Maes; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
Cancer chemotherapy and pharmacology 1995;35(3):237-45.
1994: J H M Schellens; A S T Planting; B A van Acker; Walter J Loos; MM de Boer-Dennert; M E L van der Burg; I Koier; R T Krediet; G Stoter; Jaap Verweij
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
Journal of the National Cancer Institute 1994;86(12):906-12.
1994: J Ma; Jaap Verweij; HJ Kolker; H E van Ingen; G Stoter; J H M Schellens
Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.
British journal of cancer 1994;69(5):858-62.
1994: A S T Planting; J H M Schellens; Swan Hoo Goey; M E L van der Burg; MM de Boer-Dennert; G Stoter; Jaap Verweij
Weekly high-dose cisplatin in malignant pleural mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(4):373-4.
1994: LJ van Warmerdam; Jaap Verweij; Hilde Rosing; J H M Schellens; R A Maes; Jos H Beijnen
Limited sampling models for topotecan pharmacokinetics.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):259-64.
1993: J H M Schellens; Walter J Loos; Jos H Beijnen; G Stoter; Jaap Verweij
Sensitive isocratic high-performance liquid chromatographic determination of a novel indoloquinone cytotoxic drug (EO9) in human plasma and urine.
Journal of chromatography 1993;615(2):309-15.